Walleye Trading
ALLO icon

Walleye Trading’s Allogene Therapeutics ALLO Stock Holding History

Walleye Trading’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,371
Closed -$76K – 5062
2022
Q1 		$76K Buy
+8,371
New +$87.2K ﹤0.01% 4366
2021
Q3 		– Sell
-1,910
Closed -$50K – 5148
2021
Q2 		$50K Buy
+1,910
New +$54.5K ﹤0.01% 4618

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Trading's ALLO Position: Q2 2022 in Review

Walleye Trading sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 8,371 shares — an estimated $76K sold.

Walleye Trading first reported a position in ALLO in Q2 2021 and held it in 2 quarters. The position peaked at $76K in Q1 2022. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

  • Walleye Trading reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Walleye Trading sold 8,371 Allogene Therapeutics shares in Q2 2022, an estimated $76K.
  • Walleye Trading first reported a position in Allogene Therapeutics in Q2 2021 and held it in 2 quarters.
  • Walleye Trading's Allogene Therapeutics position peaked at $76K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Walleye Trading's 13F filing for Q2 2022, filed 8 Aug 2022.